Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Patritumab deruxtecan (HER3-DXd), an antibody-drug conjugate (ADC), comprises a fully human anti-HER3 IgG1 monoclonal antibody, Patritumab, linked to a topoisomerase I inhibitor payload through a tetrapeptide-based cleavable linker, demonstrating anticancer activity [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | Patritumab deruxtecan (HER3-DXd), an antibody-drug conjugate (ADC), comprises a fully human anti-HER3 IgG1 monoclonal antibody, Patritumab, linked to a topoisomerase I inhibitor payload through a tetrapeptide-based cleavable linker, demonstrating anticancer activity [1]. |
In vitro | Patritumab deruxtecan exhibits activity against breast cancer cells expressing HER3 mutations, regardless of HER2 overexpression [1]. It binds to the surface of all HER3 mutants and HER3 WT MDA-MB-231 cells in a concentration-dependent manner (0-100 nM), but does not bind to HER3^EV cells [1]. |
Synonyms | U3-1287, HER3-DXd |
Molecular Weight | N/A |
CAS No. | 2227102-46-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Patritumab deruxtecan 2227102-46-5 U3-1287 HER3-DXd inhibitor inhibit